Stephen Chang is a human geneticist with over 32 years of commercial experience in life sciences, focusing on stem cells, cell and gene therapy, and drug development. He is an entrepreneur, scientific leader, and business strategist specializing in small company startups and non-profits in the life science sector. This expertise allows him to provide strategic guidance on cutting-edge genetic technologies and their potential market applications, as well assessing the commercial potential of novel therapies, helping clients prioritize their R&D efforts and navigate the complex landscape of regulatory requirements specific to genetic innovations.

​

Stephen's track record includes successful drug development, with recent positive outcomes in gene therapy and complex biologicals. This translational experience is crucial for accelerating the pathway from laboratory discoveries to marketable products, identifying potential hurdles in the development process and devising strategies to overcome them, while optimizing the design of clinical trials to demonstrate both efficacy and commercial viability. As an entrepreneur and business leader, Stephen brings valuable insights into the organizational and strategic aspects of commercialization. He also offers guidance on organizational structure to support efficient drug development and commercialization, leveraging his experience to help build effective teams and foster a culture of innovation. His expertise spans a wide range of therapeutic areas and technologies, including genomics, precision health, and biologics manufacturing. Most recently, Stephen has achieved successes in drug development, including Instilligen rAd-fin/syn3 (in PDUFA review) and Intravail diazepam (approved).